Education
About Us
Working with TipRanks
Follow Us
Zymeworks (ZYME)
:ZYME
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.97 - $17.70
Previous CloseN/A
Volume35.38K
Average Volume (3M)710.53K
Market Cap
$768.11M
Enterprise Value$885.76M
Total Cash (Recent Filing)-$15.16M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Apr 30, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding69,576,880
10 Day Avg. Volume659,187
30 Day Avg. Volume710,528
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.60
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.61
Enterprise Value/Ebitda-8.36
Forecast
1Y Price Target
$22.00Price Target Upside110.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Zymeworks News
PremiumCompany Announcements
Zymeworks to Engage Investors at Upcoming Conferences
PremiumCompany Announcements
Zymeworks to Present Promising Cancer Therapy Data at AACR Meeting
---
Bulls Say, Bears Say
Bulls Say
Analyst RatingsAnalyst coverage has been initiated at an OUTPERFORM rating for ZYME.
Drug ApprovalsPembrolizumab with trastuzumab and chemotherapy has been granted traditional approval for certain cancer settings, which was largely expected due to updated results.
Financial OutlookZymeworks' balance sheet resources should be sufficient to fund operations into the second half of 2027.
Bears Say
Financial PerformanceZymeworks recorded a net loss of $0.31 per share, wider than the previously forecasted net loss of $0.12 per share, primarily due to lower-than-expected revenue.
Market CompetitionFRa is a crowded target area, which could see overlap with other emerging targets like CDH6, posing a challenge to ZW191.
Stock PerformanceShares are down compared to the sector, due to limited internal catalysts and high expectations for zani's Ph3 trial in GEA.
---
Ownership Overview
22.79% Insiders
8.17% Mutual Funds
1.06% Other Institutional Investors
53.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZYME FAQ
What was Zymeworks’s price range in the past 12 months?
Zymeworks lowest stock price was $7.97 and its highest was $17.70 in the past 12 months.
What is Zymeworks’s market cap?
Zymeworks’s market cap is $768.11M.
When is Zymeworks’s upcoming earnings report date?
Zymeworks’s upcoming earnings report date is Apr 30, 2025 which is in 22 days.
How were Zymeworks’s earnings last quarter?
Zymeworks released its earnings results on Mar 05, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.099 by -$0.211.
Is Zymeworks overvalued?
According to Wall Street analysts Zymeworks’s price is currently Undervalued.
Does Zymeworks pay dividends?
Zymeworks does not currently pay dividends.
What is Zymeworks’s EPS estimate?
Zymeworks’s EPS estimate is -0.68.
How many shares outstanding does Zymeworks have?
Zymeworks has 69,576,880 shares outstanding.
What happened to Zymeworks’s price movement after its last earnings report?
Zymeworks reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.099. Following the earnings report the stock price went down -7.967%.
Which hedge fund is a major shareholder of Zymeworks?
Currently, no hedge funds are holding shares in ZYME
---
Zymeworks Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (110.93% Upside)
$22.00 (110.93% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 347.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $31.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.08%
12-Months-Change
Fundamentals
Return on Equity
-30.54%
Trailing 12-Months
Asset Growth
-20.28%
Trailing 12-Months
Company Description
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
---
ZYME Company Deck
---
ZYME Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected significant achievements in regulatory approvals and strategic partnerships, indicating strong progress and an optimistic outlook for Zymeworks. Despite some financial setbacks such as increased net loss and a program discontinuation, the company maintains a solid financial position and continues to innovate across its pipeline.Read More>---
ZYME Stock 12 Month Forecast
Average Price Target
$22.00
▲(110.93% Upside)
Technical Analysis
Arcus Biosciences
―
Vir Biotechnology
―
Nurix Therapeutics
―
Pharvaris
―
Mineralys Therapeutics, Inc.
―
Best Analysts Covering ZYME
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+34.77%
reiterated a buy rating last month
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +34.77% per trade.
---